Enoxaparin (Lovenox)
Also known as Clexane, LMWH, or Xaparin.
General information
Class/mechanism: Low molecular weight heparin, binds to antithrombin III, accelerating its activity and inhibiting factor Xa and thrombin.[1][2][3]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Brief patient counseling information can be found on page 10 of the package insert[1]
- Enoxaparin (Lovenox) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 3/29/1993: Initial FDA approval: prevention of DVT following hip replacement
Also known as
Precise Name: Enoxaparin sodium (RXCUI 221095)
| Synonyms | |||||||
|---|---|---|---|---|---|---|---|
| Cardinex | Clexan | Clexane DUO | Clexane T | Clexan Forte | Cutenox | Enoxaparin | Lmwx |
| Lovenox | Lovenox HP | Markparin | Microparin | Noxprin | |||